Head-to-head · WeighScore
Medical Health Institute vs Push Health
The verdict
Push Health takes it — 56.2/100 to 53.3/100.
Push Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Push Health is a large US telehealth platform that routes brand-name GLP-1 prescriptions (Ozempic, Zepbound, Mounjaro) through a 55,000+ pharmacy network.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Medical Health Institute | Push Health |
|---|---|---|
| WeighScore | 53.3/100 | 56.2/100 |
| Grade | C | C |
| Scorecard rank | #469 | #419 |
| Semaglutide | Not disclosed | $950/mo (brand-name) |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #469 · C
Strengths
- Operating entity disclosed: Medical Health Institute, LLC, with full Pinecrest, FL address and phone
- Named medical director (Amy Wecker, MD) plus four more named clinicians on the about page
- Three care pathways with starting-price anchors: $99 TRT / $129 peptides / $149 weight-loss
- LegitScript Certified with a footer verification link
- HIPAA compliance claimed
Where it loses points
- GLP-1 medication options (semaglutide vs tirzepatide; compounded vs brand) not shown — gated behind the intake funnel
- Pharmacy partner not named — only generic 'FDA-regulated facilities' language
- State availability not disclosed
- Several subpages (/weight-loss, /pricing, /products, /faq) returned server errors during verification
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #419 · C
Strengths
- Brand-name-only GLP-1 distribution (Ozempic, Zepbound, Mounjaro)
- 55,000+ pharmacy network per competitor sources
- LegitScript certified per competitor sources
- Listed in both competitor directories
Where it loses points
- Brand-name-only — no compounded option
- Stub entry — exact pricing, insurance coordination, and clinician workflow need YMYL verification
- Confidence LOW until verified
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.